
Figure 1: ROC curve for NLR to predict patient efficacy
clinical data | cases | CD133 Positive expression (cases) |
(χ2/P) | CD44 Positive expression (cases) |
(χ2/P) | NLR | NLR | (χ2/P) |
<2.645 | ≥2.645 | |||||||
Gender | 0.205 /0.651 |
0.521 /0.470 |
1.334 /0.248 |
|||||
male | 68 | 54 | 57 | 32 | 36 | |||
female | 52 | 43 | 46 | 30 | 22 | |||
age | 0.155 /0.694 |
1.725 /0.189 |
0.927 /0.336 |
|||||
>60 years | 67 | 55 | 60 | 32 | 35 | |||
≤60 years | 53 | 42 | 43 | 30 | 23 | |||
Tumor site | 1.805 /0.179 |
0.638 /0.424 |
0.008 /0.930 |
|||||
Peripherin | 46 | 40 | 38 | 24 | 22 | |||
Central type | 74 | 57 | 65 | 38 | 36 | |||
Pathological stage | 7.286 /0.063 |
1.664 /0.645 |
13.661 /0.003 |
|||||
Phase I | 14 | 8 | 11 | 12 | 2 | |||
Phase II | 29 | 23 | 26 | 19 | 10 | |||
Phase III | 37 | 30 | 33 | 17 | 20 | |||
Phase IV | 40 | 36 | 33 | 14 | 26 | |||
Pathological type | 2.933 /0.087 |
1.914 /0.167 |
0.036 /0.850 |
|||||
Squamous cell carcinoma |
61 | 53 | 55 | 31 | 30 | |||
Adenocarcinoma | 59 | 44 | 48 | 31 | 28 | |||
Degree of differentiation |
11.120 /0.004 |
7.792 /0.020 |
5.570 /0.062 |
|||||
Hypodifferentiation | 70 | 62 | 63 | 33 | 37 | |||
Mesodifferentiation | 41 | 31 | 35 | 21 | 20 | |||
Highly differentiated | 9 | 4 | 5 | 8 | 1 | |||
Tumor diameter | 2.295 /0.130 |
0.411 /0.521 |
5.345 /0.021 |
|||||
>3 cm | 72 | 55 | 63 | 31 | 41 | |||
≤3 cm | 48 | 42 | 40 | 31 | 17 | |||
Lymph node metastasis |
6.662 /0.010 |
4.964 /0.026 |
6.509 /0.011 |
|||||
have | 84 | 73 | 76 | 37 | 47 | |||
no | 36 | 24 | 27 | 25 | 11 |
Table 1 : The Association between CD44, CD133, and NLR and the Pathological Characteristics of NSCLC Patients
Figure 1: ROC curve for NLR to predict patient efficacy
Figure 2: Grouping basis of CD44 and CD133 Immuno histochemical Expression,Cale Bar: 100 μm
Figure 3: Percentage of Different Grades of CD44 and CD133 in Each Group
a: Impact of CD44 grouping on OS
b: Impact of CD133 grouping on OS;
c: Impact of NLR grouping on OS
Figure 4: Kaplan-Meier survival curve analysis
Tables at a glance
Figures at a glance